South Korea vows support for biopharmaceutical, auto sectors over US tariffs

South Korea's government announced it will provide additional support to key export industries, particularly biopharmaceutical and auto sectors, in anticipation of tariffs from the U.S. The support for biopharma will be formulated once details of U.S. tariffs are available, while additional measures may supplement existing support packages for automakers, chipmakers, and steel manufacturers. These actions follow recent trade talks with the U.S. as South Korea seeks tariff exemptions, despite strong semiconductor exports offsetting some trade tension impacts.

Analysis

The South Korean government is proactively addressing anticipated U.S. tariffs by pledging additional support for key export industries, particularly the biopharmaceutical and automotive sectors. This response comes as the U.S. signals moves to protect domestic pharmaceutical manufacturing, potentially through new import tariffs, which could impact South Korea's $9.59 billion pharmaceutical export market (2024 figures), of which 16% is U.S.-bound. While overall South Korean exports demonstrated unexpected resilience last month, largely driven by strong semiconductor demand, the auto sector is already exhibiting signs of strain from existing global trade tensions. Seoul is concurrently pursuing diplomatic solutions, with ongoing technical discussions aimed at securing tariff exemptions via a comprehensive trade package expected by early July. The situation carries a cautious sentiment (score: -0.2) and moderate potential market impact (score: 0.4), underscoring the uncertainty for affected industries pending further details on U.S. tariff specifics and the concrete nature of Korean governmental support measures.

Key Decisions for Investors

• Investors should closely monitor the outcome of U.S.-South Korea trade negotiations, particularly the details of any trade package by early July, as specifics on tariffs and exemptions will significantly influence the outlook for exposed sectors like biopharmaceuticals and automotives.
• It is prudent to re-evaluate exposure to South Korean biopharmaceutical companies, considering their notable U.S. export dependency (16% of $9.59 billion in 2024 pharma exports), and auto manufacturers, which are already showing signs of stress, while awaiting clarification on the scale and efficacy of pledged government support.
• Consider the relative resilience observed in the South Korean semiconductor sector as a potential differentiating factor within Korean market allocations, but remain vigilant for broader trade war escalations that could impact even currently robust segments.